Research profile
Tirzepatide
Tirzepatide acts on the GIP and GLP-1 receptors, which are involved in appetite and glucose regulation.
- Phase 3 clinical trial
- Evaluation only
SURMOUNT-1 · 72 weeks
Mean weight change
- Highest-dose group
- −20.9%
- Placebo
- −3.1%
2,539 adults with obesity or with overweight and a weight-related complication. The trial excluded diabetes.
Phase 3 randomized, double-blind, placebo-controlled trial.
How it works
GIP and GLP-1 are hormones involved in the body’s response to food. Tirzepatide activates both receptors. Researchers study how that affects blood sugar, appetite, and body weight.
Tolerability
| Outcome | Highest-dose group | Placebo |
|---|---|---|
| Nausea | 31.0% | 9.5% |
| Diarrhea | 23.0% | 7.3% |
| Stopped due to adverse events | 6.2% | 2.6% |
SURMOUNT-4
What happened after stopping?
After 36 weeks on tirzepatide, participants were randomized to continue it or switch to placebo. Over the next 52 weeks, average weight fell a further 5.5% in the continuation group and rose 14.0% in the placebo group, measured from randomization.
What remains uncertain
Both trials excluded people with diabetes. The withdrawal trial randomized people who completed the initial treatment period. The findings leave open how well the results generalize to other groups.